The global continuous glucose monitoring systems market size was valued at USD 5.24 billion in 2025 and is projected to grow from USD 6.35 billion in 2026 to USD 29.57 billion by 2034, registering a CAGR of 21.2% during the forecast period from 2026 to 2034. North America dominated the continuous glucose monitoring systems market with a market share of 42.35% in 2025.
Continuous glucose monitoring (CGM) systems are medical devices designed to continuously measure and track glucose levels in the interstitial fluid throughout the day and night. These systems typically consist of a wearable sensor, a transmitter, and a receiver or compatible smart device that provides real-time glucose readings, trends, and alerts. Continuous glucose monitoring systems enable individuals with diabetes and healthcare providers to monitor glucose fluctuations more effectively, support timely treatment decisions, improve glycemic control, and reduce the risk of hypoglycemia and hyperglycemia. They are widely used in diabetes management to enhance patient outcomes, facilitate personalized care, and improve overall quality of life.
Download a Free Sample To learn more about this report,
Over-the-Counter Access Broadens the Role of Continuous Glucose Monitoring
Consumer access to glucose-monitoring technology is expanding beyond traditional insulin-dependent users, creating a broader role for Continuous Glucose Monitoring systems in everyday glucose awareness and lifestyle management. In June 2026, the FDA cleared Dexcom’s Stelo Glucose Biosensor System as the first over-the-counter Continuous Glucose Monitor for children, extending its indication to people aged 2 years and older who do not use insulin; the system provides glucose measurements and trends every 15 minutes. This regulatory expansion is consequently broadening Continuous Glucose Monitoring applications across pediatric and non-insulin populations while integrating glucose insights into routine health management.
Longer-Wear Sensors Reshape Continuous Glucose Monitoring Convenience
Sensor replacement requirements are encouraging manufacturers to extend wear duration while maintaining continuous measurement and reliable data transmission. The FDA’s 2026 device records include the Dexcom G7 15 Day Continuous Glucose Monitoring System, while the Stelo system cleared for pediatric use in June 2026 provides up to 15 days of sensor wear before replacement. Longer operating periods are therefore reducing replacement frequency and simplifying continuous monitoring routines, supporting more convenient long-term use of wearable glucose-monitoring systems.
Expanding Diabetes Care and Remote Patient Management Drives Market
The expanding population requiring glucose management increases the need for technologies that provide continuous and actionable glucose information. A larger patient base creates broader requirements for CGM sensors, transmitters, receivers, and associated monitoring solutions across diabetes care settings. Higher patient volumes can strengthen recurring demand for CGM devices and replacement components throughout the treatment cycle. Greater reliance on continuous monitoring can also expand the installed base of CGM systems across long-term diabetes management programs.
Healthcare providers and patients increasingly require connected monitoring tools that support remote review of glucose data and ongoing treatment management. CGM systems can transmit glucose information to smartphones, digital health platforms, and clinical monitoring systems, supporting more continuous interaction between patients and care teams. The expansion of remote care workflows can increase demand for connected CGM platforms and supporting digital services. Integration with telehealth and digital care ecosystems can further expand the use of connected glucose monitoring across distributed care settings.
Sensor and Consumable Costs and Skin Reactions and Wearability Issues Restrain Market Expansion
CGM systems require recurring expenditure on sensors and, depending on the device, transmitters or other consumable components. These ongoing costs can create affordability barriers for patients who lack adequate insurance coverage or reimbursement support. The recurring financial burden can limit adoption among cost-sensitive users and reduce access to continuous monitoring over extended treatment periods. Higher replacement requirements can further increase the total cost of long-term CGM use and discourage sustained adoption.
Adhesives and sensor placement can cause skin irritation, discomfort, or other local reactions for some CGM users, particularly during prolonged or repeated sensor wear. Such issues can affect user acceptance and contribute to discontinuation or inconsistent device use. Concerns over comfort and skin tolerance can therefore restrict sustained adoption and limit the expansion of CGM use among sensitive patient groups. Repeated exposure to adhesives and sensor components can further create usability barriers for patients requiring continuous monitoring over extended periods.
Gestational Diabetes Monitoring and Sports and Wellness Monitoring Offers Growth Opportunities
Maternal healthcare providers can use CGM systems to monitor glucose patterns among women managing gestational diabetes and support more detailed treatment decisions. CGM manufacturers can develop pregnancy-focused monitoring solutions and specialized clinical programs for hospitals and obstetric care providers. These applications can create additional revenue through specialized devices, clinical partnerships, and patient-monitoring services. Integration with maternity care pathways can further expand opportunities for CGM providers across hospitals, clinics, and specialized diabetes programs.
Sports performance companies and wellness providers can use CGM technology to study glucose responses associated with nutrition, exercise, and physical activity. Device manufacturers can develop consumer-oriented analytics, coaching platforms, and performance-focused monitoring services around CGM data. Such applications can broaden the customer base and create new revenue streams through software subscriptions, analytics, and specialized wellness programs. Partnerships with fitness platforms and performance programs can further create commercial opportunities for CGM manufacturers beyond traditional diabetes-care applications.
Interoperability Gaps and CGM Integration and Data Privacy Requirements Hinders Market Growth
Differences in data formats, communication protocols, and software architectures can make integration between CGM devices, smartphones, electronic health records, and diabetes-management platforms difficult. Such interoperability gaps can increase integration requirements for manufacturers and healthcare providers while limiting seamless data exchange across platforms. Fragmented digital ecosystems can therefore make large-scale deployment and cross-platform collaboration more complex for CGM providers.
Connected CGM systems generate sensitive health information that requires appropriate safeguards across devices, applications, cloud platforms, and healthcare networks. Manufacturers and digital health providers must coordinate data governance, cybersecurity, consent management, and regulatory compliance across multiple technology layers. These requirements can increase operational complexity and slow the deployment of integrated CGM services across different healthcare environments.
The sensors segment accounted for a share of 52.82% in 2025 and is expected to grow at a CAGR of 11.92% during the forecast period 2026-2034, owing to their critical role in continuously measuring glucose levels and providing real-time data for effective glucose management. The transmitters segment supports market growth by collecting and wirelessly transmitting glucose data from sensors to connected devices, while the receivers segment enables users and healthcare professionals to access and interpret glucose readings for monitoring and treatment decisions.
Request Customizationto receive a tailored report.
The adult population (>14 years) segment accounted for a share of 76.36% in 2025, owing to the high prevalence of diabetes among adults and the increasing adoption of continuous glucose monitoring for ongoing glucose management and treatment optimization. The child population (≤14 years) segment is expected to grow at a CAGR of 11.58% during the forecast period 2026-2034, driven by increasing awareness of diabetes management in children, the need for continuous monitoring, and growing adoption of wearable glucose monitoring technologies among pediatric patients.
The homecare settings segment accounted for a share of 63.53% in 2025 and is expected to grow at a CAGR of 11.74% during the forecast period 2026-2034, owing to the convenience of continuous glucose monitoring outside clinical environments and increasing preference for remote and self-managed diabetes care. The hospitals segment contributes to market growth through the use of continuous glucose monitoring systems for inpatient glucose monitoring, treatment management, and clinical decision-making.
Speak to an Analystto discuss market opportunities.
The North America continuous glucose monitoring systems market accounted for the largest regional share of 42.35% in 2025, supported by high diabetes prevalence, established reimbursement systems, and broad availability of wearable glucose-monitoring technologies.
The U.S. continuous glucose monitoring systems market is positioned to benefit from the projected expansion of the diabetes population over the long term. The International Diabetes Federation estimates that the number of adults aged 20–79 with diabetes in the U.S. will increase from 38.5 million in 2024 to 43.0 million by 2050. The expanding patient population can increase demand for continuous glucose monitoring as healthcare providers increasingly use real-time glucose data for diabetes management.
Canada's continuous glucose monitoring systems market is expected to benefit from the country's projected long-term increase in diabetes prevalence and continued policy support for access to diabetes technologies. Canada's Framework for Diabetes identifies access to diabetes devices, medicines, and financial supports as one of its six core components, while the Public Health Agency of Canada continues diabetes surveillance and management initiatives through 2025–26. The framework reports that more than 3 million Canadians, or 8.9% of the population, have diagnosed diabetes, with prevalence increasing by an average of 3.3% annually after adjustment for population aging.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific continuous glucose monitoring systems market is expected to grow at a CAGR of 13.68% during the forecast period, showcasing the fastest-growing regional market. Expansion is supported by the large diabetic population across China and India, increasing use of digital health technologies, and greater clinical emphasis on real-time glucose monitoring.
Japan's continuous glucose monitoring systems market is expected to benefit from the country's substantial and aging diabetes population. The International Diabetes Federation estimates that 10.8 million adults aged 20–79 had diabetes in Japan in 2024, placing the country among the world's leading markets by diabetes population. Japan has also established reimbursement for CGM technology, with the Ministry of Health, Labour and Welfare listing the Dexcom G6 CGM system among medical devices covered under health insurance.
China's continuous glucose monitoring systems market is positioned for sustained expansion as the country's diabetes burden remains exceptionally large. The International Diabetes Federation estimates that 148.0 million adults aged 20–79 had diabetes in China in 2024, with the number projected to reach 168.3 million by 2050. The 2025 IDF estimates also indicate that 49.7% of adults with diabetes in China were undiagnosed, highlighting substantial potential for improved glucose monitoring and diabetes management.
South Korea strengthened the clinical role of continuous glucose monitoring through its 2025 diabetes management guidelines. The 2025 Clinical Practice Guidelines for Diabetes Management in Korea recommend that adults with type 1 diabetes use real-time CGM as close to daily as possible, while also recommending regular CGM use for adults with type 2 diabetes using multiple daily injections or insulin pumps. The guidelines also state that adults with type 2 diabetes receiving basal insulin therapy may use real-time CGM.
India's continuous glucose monitoring systems market gained momentum in 2025 through the introduction of more accessible and minimally invasive glucose-monitoring technologies. In August 2025, Abbott launched the FreeStyle Libre 2 Plus in India, providing automatic glucose readings every minute and optional high- and low-glucose alarms directly to compatible smartphones. Separately, IIT Madras researchers developed and patented a cost-effective, minimally invasive glucose-monitoring device in November 2025, highlighting domestic innovation aimed at improving affordability and accessibility.
The Europe continuous glucose monitoring systems market accounted for a share of 27.18% in 2025, supported by established diabetes-care systems, increasing digitalization of healthcare, and broader integration of wearable glucose-monitoring technologies.
The U.K. continuous glucose monitoring systems market is expected to benefit from a projected increase in the country's diabetes population. UK government projections estimate that the number of people with diabetes in England could reach approximately 4.8 million by 2030, representing around 9.3% of the population aged 16 and over. The NHS has also established broad access to CGM, with CGM available to people with type 1 diabetes and a five-year phased implementation strategy for hybrid closed-loop technologies beginning in 2025.
Germany's continuous glucose monitoring systems market is expected to benefit from the country's aging population and the projected expansion of diabetes requiring insulin therapy. Estimates indicate that the number of people aged 55–74 living with type 2 diabetes in Germany could reach 3.9 million by 2030, according to projections from the German Diabetes Center cited by the German scientific information service. Germany's federal demographic projections also show the population aged 67 and above increasing from 16.4 million in 2021 to around 18.8 million by 2030 under a moderate demographic scenario.
France's continuous glucose monitoring systems market is positioned to benefit from demographic changes that are expected to increase the population requiring long-term diabetes management. INSEE's latest population projections show that France's population aged 65–74 is expected to increase from 7.6 million in 2026 to 7.8 million in 2030, while the population aged 75 and above is projected to rise from 2.4 million to 2.5 million over the same period. The aging population can increase the healthcare burden associated with chronic diseases such as diabetes and strengthen demand for technologies that facilitate ongoing glucose monitoring.
The Middle East and Africa continuous glucose monitoring systems market is expected to grow at a CAGR of 9.86% during the forecast period, supported by a high diabetes burden, increasing healthcare expenditure, and growing attention to earlier diagnosis and continuous disease management.
The U.A.E. continuous glucose monitoring systems market was supported by the country's substantial diabetes burden in 2025. The 2025 estimates from the International Diabetes Federation indicate that approximately 1.27 million adults aged 20–79 in the UAE were living with diabetes, representing a diabetes prevalence of 16.5%. The same estimates indicate that 20.7% of the adult population had diabetes when expressed using the country's national prevalence measure.
Africa's continuous glucose monitoring systems market received further support from the growing diabetes burden documented during 2025. WHO reported in November 2025 that more than 24 million adults aged 20–79 in the WHO African Region were living with diabetes, with the number projected to more than double to 60 million by 2050. WHO also highlighted that nearly half of people with diabetes in the region remain undiagnosed, creating a substantial need for improved detection and long-term monitoring.
The continuous glucose monitoring systems market competitive landscape is highly concentrated, with competition comprising specialized CGM manufacturers, medical device companies, diabetes-care technology providers, and diversified healthcare companies. Key players such as Pfizer Inc., Baxter International Inc., Senseonics, Dexcom Inc., and Abbott Laboratories collectively are estimated to account for approximately 60% of the global continuous glucose monitoring systems market share; however, the market is principally dominated by Abbott, Dexcom, and Medtronic, which together accounted for 96.82% of 2025 CGM shipments in one recent industry analysis.
Established players compete primarily on sensor accuracy, wear duration, clinical validation, and digital connectivity. Emerging and regional players in the CGM ecosystem compete through implantable and minimally invasive technologies, compact sensor designs, specialized applications, and cost-effective monitoring solutions, while expanding into diabetes management and connected health platforms.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Germany Surgical Equipment Market Size, Share and Forecast to 2034
Europe Surgical Equipment Market Size, Top Share and Forecast to 2034
Biofeedback Instrument Market Size, Share, Growth, Analysis, 2034
Cardiac Assist Devices Market Size, Share, Growth, 2034
Radiosurgery Market Size, Share, Growth, Analysis, Report, 2034
Interventional Cardiology Devices Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com